Atacand Advisory Cmte. To Focus On Concomitant Use With ACE Inhibitors
This article was originally published in The Pink Sheet Daily
Executive Summary
The focus of FDA's Cardiovascular & Renal Drugs Advisory Committee review of AstraZeneca's Atacand Feb. 24 will be narrowed to a discussion of concomitant use with angiotensin-converting enzyme inhibitors in treating congestive heart failure
You may also be interested in...
AstraZeneca's Atacand Heart Failure Indication Clears FDA Ahead Of Cmte. Review
The agency approves candesartan for treatment of heart failure to reduce cardiovascular mortality and hospitalizations. The angiotensin receptor blocker is the first product in its class to receive the claim. Approval comes two days before an FDA advisory panel review.
AstraZeneca's Atacand Heart Failure Indication Clears FDA Ahead Of Cmte. Review
The agency approves candesartan for treatment of heart failure to reduce cardiovascular mortality and hospitalizations. The angiotensin receptor blocker is the first product in its class to receive the claim. Approval comes two days before an FDA advisory panel review.
AstraZeneca’s Atacand For Congestive Heart Failure To Receive FDA Cmte. Review
The agency’s cardio-renal committee will consider three sub-indications for Atacand in the treatment of congestive heart failure. The meeting will be held on Feb. 24.